#1#2Disclaimer General The information contained in this Investor Presentation (“Presentation”) has been prepared by Nutex Health Inc. (“NUTX” or the “Company”) for investors, solely for informational purposes. The Presentation has been prepared to assist prospective investors in making their own evaluation of the Company and does not purport to be all inclusive or to contain all of the information a prospective or existing investor may desire. The Presentation shall not form the basis of any contract or commitment. Information provided in this Presentation speaks only as of the date hereof and is subject to change. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data set forth in this Presentation. This Presentation does not constitute investment, legal, tax or other advice, and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Nothing set forth herein should be regarded or relied upon as a representation, warranty or prediction that NUTX will achieve or is likely to achieve any particular future result. While NUTX are not aware of any misstatements regarding any information in this Presentation, NUTX or any of its respective affiliates, officers, directors or representatives makes any representation or warranty, express or implied, as to the accuracy or completeness thereof. Readers of this Presentation should consult their own counsel and tax and financial advisors as to legal and related matters concerning the information described herein. This Presentation does not purport to contain all the information or factors that may be required to make a full analysis of NUTX. Viewers of this Presentation should each make their own evaluation of NUTX and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. This Presentation also contains estimates and other statistical data made by independent parties and by NUTX relating to market size and growth and other data about NUTX's industry and peer companies. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. To the fullest extent permitted by law, in no circumstances will NUTX or any of its subsidiaries, affiliates, representatives, directors, officers, advisers or agents be liable for any direct, indirect or consequential losses arising from the use of this Presentation, the information contained within this Presentation, or otherwise arising in connection there with, including any investment in shares of NUTX. In addition, projections, assumptions, and estimates of NUTX's future performance and the future performance of the markets in which NUTX competes are necessarily subject to a high degree of uncertainty and risk. CONFIDENTIAL 2#3Forward looking statements Certain statements and information included in this Presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this Presentation, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-Q for the period ended September 30, 2022 under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this Presentation. CONFIDENTIAL 3#4#5#6Our mission, vision, and values Our Mission To make exceptional concierge-level health care more accessible to all communities, with a practice centered on patient experience and satisfaction Our Vision To be leaders in individualized patient care and innovators in the future of health care Our Values Patient care is our number one priority - every single decision that we make as a company revolves around creating the best possible patient care CONFIDENTIAL 6#7#8We became a public company through a Reverse Merger NUTEX Transaction overview Rationale HEALTH Micro-hospitals CLINIGENCE HEALTH Value-based care Nutex Health announced a reverse merger with Clinigence Holdings ■ Clinigence is a publicly traded technology-enabled population health management company whose platform combines medical management, data analytics and risk-bearing provider networks ■ Announced November 2021 and closed effective April 2022 ■ Creates a leader in population-based value-based care Integration of Nutex's micro-hospital platform with the data and population health management services of Clinigence to drive attractive growth and operating synergies CONFIDENTIAL 8#9Nutex at-a-glance ■ Comprehensive and integrated care delivery platform comprised of: ■ Hospital Division - Patient-centric network of micro-hospitals, specialty hospitals, and hospital outpatient departments ■ Population Health Management Division Provides management services to provider networks, hospitals, and health systems - Reverse merger delivered medical management, data analytics and risk bearing provider networks ■Aligned physician incentive model Rewards quality of care to patients Provides long-term alignment through shareholder ownership structures Company highlights 21 owned and operating facilities 22,000+ lives under management 800+ physicians 3.1M active patient records on the population health. platform >95% physician retention rate 10,700+ data sources CONFIDENTIAL 9#10#11#12Case study: Dallas, TX Over the course of five years, Nutex expanded its footprint from one to four centers in the Dallas market, gaining market share in a disciplined and highly strategic approach, using a single hospital license and the Hospital Outpatient Department (HOPD) approach 4 287 30 Newark Rhome HI 820 Lake Worth? White Settlement 183 Benbrook (183) H Haslet Saginaw 30 380 35W Justin Ponder 35W 35W COPPELL ER Fort Worth Roanoke Koll Haltom City (377) North Richland Hills Argyle 820 (380 HR Denton (114) THE COLONY ER HOSPITAL Flower Mound Southlake Grapevine 360 Euless Arlington Cross Roads Highland Village (360) Lewisville Coppell 3 Grand Prairie 635 Irving (380 Little Elm The Co Carrollton 35E 1 Farmers Branch (289) Frisco Addison 2 University Park Dallas 35E (121) 380 4 Plano Richardson 635 Allen 175 (380) McKinney Fairview (190 Murphy Garland 635 Luc Balch Springs Mesquite Rowlett Sun Wylie Princeton (205 WEST PLANO EMERGENCY ROOM Josephine Nevada Rockwall Heath Lavon Forney Farmersville Heartland Fate 30 WYLIE ER 24/7 EMERGENCY ROOM Royse City McLendon-Chisholm 205 557 Meri 276 80 Te Wilsor 1 February 2017: Acquired The Colony Hospital April 2021: 2 Acquired West Plano ER and placed it under The Colony's license as an HOPD May 2021: 3 Acquired Coppell ER and placed it under The Colony's license as an HOPD 4 September 2022: Acquired Wylie ER and placed it under The Colony's license as an HOPD Nutex plans to use a similar strategy as a growth portal for all current and future hospitals around the country CONFIDENTIAL 12#13Our focus areas represent a massive market opportunity Population Health Value-Based Care Total Addressable Market -$280bn+ Targeted Addressable Market ~$110bn+ ● ● Expansive additional addressable market with population health strategy Total Emergency Department Market All payors All levels of acuity Targeted Emergency Department Market Commercial pay ED visits Mid-acuity (emergent to semi-urgent) Source: U.S. Department of Commerce, U.S. Department of Health and Human Services Centers for Disease Control and Prevention, National Hospital Ambulatory Medical Care Survey: 2018 Emergency Department Summary Tables Note: 2022 Segal Health Plan Cost Trend Survey Report indicates the average cost of an ER visit to be as high as $1,900 CONFIDENTIAL 13#14#15Nutex has a differentiated model Care delivery model Hospital / in-patient services Physician ownership/ partnership model? Profitable? Risk-bearing / value-based care / population health capabilities Traditional hospital ER / micro-hospitals / urgent care Acute primary care / severe treatment centers with extended hours ✓ / X x ✓ | x x Existing care models Traditional facility- based care Facility-based care setting (i.e., hospital, rehab centers, ASCs, etc.) x ✓ | x x Next-gen clinic-based primary care Standalone, tech- enabled PCP-led internal care team x x ✓ | x 1 Nutex's approach NUTEX HEALTH Micro-hospitals with wraparound IPA model CONFIDENTIAL 15#16#17#18#19#20#21#22#23#24#25#26#27#28#29#30